Eagle Pharmaceuticals - EGRX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $26.00
  • Forecasted Upside: 37.86%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.86
▲ +0.01 (0.05%)

This chart shows the closing price for EGRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eagle Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EGRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EGRX

Analyst Price Target is $26.00
▲ +37.86% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Eagle Pharmaceuticals in the last 3 months. The average price target is $26.00, with a high forecast of $26.00 and a low forecast of $26.00. The average price target represents a 37.86% upside from the last price of $18.86.

This chart shows the closing price for EGRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Eagle Pharmaceuticals. This rating has held steady since August 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/15/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2023Piper SandlerLower Target$31.00 ➝ $26.00Low
3/14/2023Piper SandlerLower Target$41.00 ➝ $31.00Low
9/1/2021Piper SandlerBoost TargetNeutral$48.00 ➝ $51.00Medium
8/9/2021William BlairReiterated RatingOutperformMedium
4/20/2020Cantor FitzgeraldReiterated RatingHold$46.00High
3/25/2020Royal Bank of CanadaReiterated RatingBuy$59.00Medium
3/2/2020Cantor FitzgeraldLower TargetNeutral$58.00 ➝ $46.00High
8/11/2019Royal Bank of CanadaReiterated RatingBuy$66.00Low
5/7/2019Cantor FitzgeraldReiterated RatingHold$58.00Low
4/24/2019MizuhoReiterated RatingHold$50.00Low
4/15/2019Cantor FitzgeraldReiterated RatingHold$58.00High
3/22/2019MizuhoBoost TargetNeutral ➝ Neutral$40.00 ➝ $41.00High
3/1/2019Royal Bank of CanadaSet TargetBuy$66.00High
2/28/2019Cantor FitzgeraldReiterated RatingHold$58.00Medium
11/7/2018MizuhoLower TargetNeutral$52.00Medium
11/2/2018Royal Bank of CanadaSet TargetBuy$64.00Medium
11/1/2018Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
10/31/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$82.00 ➝ $54.00High
10/30/2018Cantor FitzgeraldSet TargetBuy$80.00High
10/3/2018Cantor FitzgeraldSet TargetBuy$80.00Low
9/20/2018Cantor FitzgeraldLower TargetOverweight ➝ Buy$81.00 ➝ $80.00High
8/24/2018Cantor FitzgeraldSet TargetBuy$81.00Low
8/8/2018Royal Bank of CanadaSet TargetBuy$84.00Medium
8/7/2018Piper Jaffray CompaniesSet TargetBuy$88.00Low
8/7/2018Cantor FitzgeraldSet TargetBuy$81.00Low
7/24/2018Piper Jaffray CompaniesSet TargetBuy$86.00Low
6/11/2018Cantor FitzgeraldInitiated CoverageOverweight$81.00High
6/11/2018MizuhoUpgradeUnderperform ➝ NeutralLow
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/10/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/9/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/8/2023
  • 8 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/10/2023
  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/9/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/8/2023

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Eagle Pharmaceuticals logo
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
Read More

Today's Range

Now: $18.86
Low: $18.35
High: $18.99

50 Day Range

MA: $25.20
Low: $18.30
High: $31.87

52 Week Range

Now: $18.86
Low: $18.02
High: $47.71

Volume

186,751 shs

Average Volume

152,537 shs

Market Capitalization

$246.90 million

P/E Ratio

377.28

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Eagle Pharmaceuticals?

The following equities research analysts have issued stock ratings on Eagle Pharmaceuticals in the last year: Piper Sandler, and StockNews.com.
View the latest analyst ratings for EGRX.

What is the current price target for Eagle Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Eagle Pharmaceuticals in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 37.9%. Piper Sandler has the highest price target set, predicting EGRX will reach $26.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $26.00 for Eagle Pharmaceuticals in the next year.
View the latest price targets for EGRX.

What is the current consensus analyst rating for Eagle Pharmaceuticals?

Eagle Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EGRX.

What other companies compete with Eagle Pharmaceuticals?

How do I contact Eagle Pharmaceuticals' investor relations team?

Eagle Pharmaceuticals' physical mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company's listed phone number is (201) 326-5300 and its investor relations email address is investors@eagleus.com. The official website for Eagle Pharmaceuticals is www.eagleus.com. Learn More about contacing Eagle Pharmaceuticals investor relations.